Back to Search
MISSAK HAIGENTZ, MD
MD
Medical Oncology Physician
NPI: 1750461240IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
210614(NY)25MA06465800(NJ)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
RUTGERS NEW JERSEY MEDICAL SCHOOL
Class of 1995
Research & Publications (13)
Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib.
PMID 19130057·Cancer Chemother Pharmacol·2009
8-other
A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies.
PMID 18981010·Clin Cancer Res·2008
3-trial
Inferior vena cava syndrome from pancreatic adenocarcinoma: successful symptom palliation with endovascular stenting.
PMID 18980442·J Palliat Med·2008
5-case
Head and neck cancer: reduce and integrate for optimal outcome.
PMID 18000360·Cytogenet Genome Res·2007
8-other
A rare case of primary lung adenocarcinoma detected by routine liquid-based cervical cytology.
PMID 17566599·Lung Cancer·2007
5-case
Differential tissue and subcellular expressionof ERM proteins in normal and malignant tissues: cytoplasmic ezrin expression has prognostic signficance for head and neck squamous cell carcinoma.
PMID 16783828·Head Neck·2006
8-other
Unusual sites of malignancies: CASE 1. Small-cell carcinoma of the hypopharynx.
PMID 15774797·J Clin Oncol·2005
5-case
Exogenous expression of H-cadherin in CHO cells regulates contact inhibition of cell growth by inducing p21 expression.
PMID 15138602·Int J Oncol·2004
7-preclinical
Indirect measurements of differential gene expression with cDNA microarrays.
PMID 14989096·Biotechniques·2004
4-observational
The BCL2-family of protein ligands as cancer drugs: the next generation of therapeutics.
PMID 12769779·Curr Med Chem Anticancer Agents·2003
6-review
Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies.
PMID 12679737·Anticancer Drugs·2003
3-trial
Chemopreventive therapeutics. Inhalation therapies for lung cancer and bronchial premalignancy.
PMID 12407778·Methods Mol Med·2003
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 195 LITTLE ALBANY ST
NEW BRUNSWICK, NJ 08901 - Phone
- (732) 235-2465
Quick Facts
- NPI
- 1750461240
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 31
- Publications
- 13
Are you this provider?
Claim Your Profile